Report copyright - Welcome & Introductions · 5/23/2017 · Phase 3 inotuzumab vs standard intensive therapy (N=326) CR: Inotuzumab ozogamicin (Ino) 81% vs chemotherapy 30% MRD
Please pass captcha verification before submit form
Please pass captcha verification before submit form